

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Huntington's disease (HD)	Huntingtin (HTT)	<i>In vitro</i> studies suggest that mismatch-containing duplex RNA that targets <i>HTT</i> could help treat HD. In fibroblasts from HD patients, duplex RNA that bound the <i>HTT</i> sequence led to <i>HTT</i> cleavage and inhibition of cytotoxic HTT. Studies are ongoing with Alynham Pharmaceuticals Inc. to chemically modify duplexes for <i>in vivo</i> testing. Next steps also include testing the duplexes in animals. SciBX 3(48); doi:10.1038/scibx.2010.1453 Published online Dec. 16, 2010	Patent and licensing status undisclosed	Hu, J. <i>et al. J. Chem. Biol.</i> ; published online Nov. 24, 2010; doi:10.1016/j.chembiol.2010.10.013 Contact: David R. Corey, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: david.corey@utsouthwestern.edu